Systems Biology for Drug Target Discovery in Acute Myeloid Leukemia
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25094618 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Svetlana Novikova und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biomedical Chemistry, Pogodinskaya 10, 119121 Moscow, Russia. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Tretinoin, Systems Biology. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Russian Science Foundation.
Abstract (Originalsprache)
Combining new therapeutics with all-trans-retinoic acid (ATRA) could improve the efficiency of acute myeloid leukemia (AML) treatment. Modeling the process of ATRA-induced differentiation based on the transcriptomic profile of leukemic cells resulted in the identification of key targets that can be used to increase the therapeutic effect of ATRA. The genome-scale transcriptome analysis revealed the early molecular response to the ATRA treatment of HL-60 cells. In this study, we performed the transcriptomic profiling of HL-60, NB4, and K562 cells exposed to ATRA for 3–72 h. After treatment with ATRA for 3, 12, 24, and 72 h, we found 222, 391, 359, and 1032 differentially expressed genes (DEGs) in HL-60 cells, as well as 641, 1037, 1011, and 1499 DEGs in NB4 cells. We also found 538 and 119 DEGs in K562 cells treated with ATRA for 24 h and 72 h, respectively. Based on experimental transcriptomic data, we performed hierarchical modeling and determined cyclin-dependent kinase 6 (CDK6), tumor necrosis factor alpha (TNF-alpha), and transcriptional repressor CUX1 as the key regulators of the molecular response to the ATRA treatment in HL-60, NB4, and K562 cell lines, respectively. Mapping the data of TMT-based mass-spectrometric profiling on the modeling schemes, we determined CDK6 expression at the proteome level and its down-regulation at the transcriptome and proteome levels in cells treated with ATRA for 72 h. The combination of therapy with a CDK6 inhibitor (palbociclib) and ATRA (tretinoin) could be an alternative approach for the treatment of acute myeloid leukemia (AML).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Biomedical Chemistry, Pogodinskaya 10, 119121 Moscow, Russia.
ORCID-Profile: Svetlana Novikova, Tatiana Tolstova, Leonid Kurbatov, Tatiana Farafonova, Natalia Soloveva, Victor Zgoda
Förderung
- Russian Science Foundation
Zitieren
APA
Novikova, S., Tolstova, T., Kurbatov, L., Farafonova, T., Tikhonova, O., Soloveva, N., Rusanov, A., & Zgoda, V. (2024). Systems Biology for Drug Target Discovery in Acute Myeloid Leukemia. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25094618
Vancouver
Novikova S, Tolstova T, Kurbatov L, Farafonova T, Tikhonova O, Soloveva N, et al. Systems Biology for Drug Target Discovery in Acute Myeloid Leukemia. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25094618
BibTeX
@article{Novikova2024,
author = {Novikova, Svetlana and Tolstova, Tatiana and Kurbatov, Leonid and Farafonova, Tatiana and Tikhonova, Olga and Soloveva, Natalia and Rusanov, Alexander and Zgoda, Victor},
title = {Systems Biology for Drug Target Discovery in Acute Myeloid Leukemia},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25094618}
}
EUVIMED